tbuckley/cabot-search huggingface dataset:
Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy.
Authors: I. Koroleva, M. V. Kopp, A. N. Kasulin, J. A. Kucheryavyy, M. J. Byakhov
Journal: Journal of Clinical Oncology (2011)

e11582 Background: Cardiotoxicity is a common and potentially devastating side effect of antineoplastic drug therapy. Combination of anthracyclines and taxanes increases frequency of cardiac dysfunction. We conducted a retrospective analisis of cardiac dysfunction of breast cancer patients during neoadjuvant and adjuvant chemotherapy and after chemotherapy. Methods: We have retrospectively analyzed toxicity in 1643 patients treated for HER2-negative breast cancer between 1993 and 2003. All patients received taxan-anthracycline–based chemotherapy regimens (paclitaxel 175 mg/m2 and doxorubicin 50 mg/m2 or docetaxel 75 mg/m2 and doxorubicin 50 mg/m2), at 21 days intervals, for 4 cycles as neoadjuvant and 4 cycles as adjuvant. All patients underwent mastectomies between 4th and 5th cycles of chemotherapy. Interval between 4th and 5th cycles was not longer then 8 weeks. ECG and Doppler-echo were performed during treatment period and follow-up period. Results: The mean age was 51.6 years (28 – 70 years). The follow-up mean was 2.9 years (1 - 5 years) after the end of chemotherapy. All patients had normal cardiac tests before chemotherapy. Early cardiotoxicity was found in 46.1% patients after 8 cycles of chemotherapy. 42,8% patients had arrhythmia or QT-prolongation after 8 cycles of chemotherapy. 81% of patients had marginal left ventricular ejection fraction (LVEF) after 8 cycles of chemotherapy. During follow-up late cardiotoxicity was diagnosed in 34.6% patients. E/A ratio was < 1 in patients with early cardiotoxicity and during follow-up. Conclusions: This results show the necessity of control of cardiac function during chemotherapy and of adaptation of treatment according to the results of Doppler-echo monitoring which is one of the most informative methods of evaluation of cardiac dysfunction after chemotherapy.
PD2-3-8: -2518 MCP-1 and Interleukin-4 VNTR polymorphisms and NSCLC risk
Authors: Ana P. Coelho, António Araújo, Cármen Calçada, An Nogal, Diana Cardoso, Ana Faria, Isabel Azevedo, Marta Soares, Raquel Catarino, Rui Medeiros
Journal: Journal of Thoracic Oncology (2007)
Randomized Trial of an Integrated Behavioral Health Home: The Health Outcomes Management and Evaluation (HOME) Study
Authors: Benjamin G. Druss, Silke A. von Esenwein, Gretl E. Glick, Emily Deubler, Cathy Lally, Martha C. Ward, Kimberly J. Rask
Journal: American Journal of Psychiatry (2016)

Behavioral health homes provide primary care health services to patients with serious mental illness treated in community mental health settings. The objective of this study was to compare quality and outcomes of care between an integrated behavioral health home and usual care.The study was a randomized trial of a behavioral health home developed as a partnership between a community mental health center and a Federally Qualified Health Center. A total of 447 patients with a serious mental illness and one or more cardiometabolic risk factors were randomly assigned to either the behavioral health home or usual care for 12 months. Participants in the behavioral health home received integrated medical care on-site from a nurse practitioner and a full-time nurse care manager subcontracted through the health center.Compared with usual care, the behavioral health home was associated with significant improvements in quality of cardiometabolic care, concordance of treatment with the chronic care model, and use of preventive services. For most cardiometabolic and general medical outcomes, both groups demonstrated improvement, although there were no statistically significant differences between the two groups over time.The results suggest that it is possible, even under challenging real-world conditions, to improve quality of care for patients with serious mental illness and cardiovascular risk factors. Improving quality of medical care may be necessary, but not sufficient, to improve the full range of medical outcomes in this vulnerable population.
Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in <i>RET</i>M918T Tumors
Authors: Veronika Mancikova, Cristina Montero-Conde, Javier Perales-Paton, Agustin Fernandez, María Santacana, Karolina Jodkowska, Lucia Inglada-Pérez, Esmeralda Castelblanco, Salud Borrego, Mario Encinas, Xavier Matias-Guiu, Mario Fraga, Mercedes Robledo
Journal: Clinical Cancer Research (2016)

Purpose: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development.Experimental Design: We performed genome-wide DNA methylation profiling assessing more than 27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors. mRNA and miRNA expression data were available for 33 and 31 tumors, respectively. Two human MTC cell lines and 101 paraffin-embedded MTCs were used for validation.Results: The most distinctive methylome was observed for RETM918T-related tumors. Integration of methylation data with mRNA and miRNA expression data identified genes negatively regulated by promoter methylation. These in silico findings were confirmed in vitro for PLCB2, DKK4, MMP20, and miR-10a, -30a, and -200c. The mutation-specific aberrant methylation of PLCB2, DKK4, and MMP20 was validated in 25 independent MTCs by bisulfite pyrosequencing. The methylome and transcriptome data underscored JAK/Stat pathway involvement in RETM918T MTCs. Immunostaining [immunohistochemistry (IHC)] for the active form of signaling effector STAT3 was performed in a series of 101 MTCs. As expected, positive IHC was associated with RETM918T-bearing tumors (P < 0.02). Pharmacologic inhibition of STAT3 activity increased the sensitivity to vandetanib of the RETM918T-positive MTC cell line, MZ-CRC-1.Conclusions: Multilayer OMIC data analysis uncovered methylation hallmarks in genetically defined MTCs and revealed JAK/Stat signaling effector STAT3 as a potential therapeutic target for the treatment of RETM918T MTCs. Clin Cancer Res; 23(5); 1334-45. ©2016 AACR.
P3-190: Postoperative 3D Conformal Radiation Therapy in Non Small Cell Lung Cancer
Authors: Rene O. Mirimanoff, Mahmut Ozsahin, Daniela Dragusanu, Hans B. Ris, Kaouthar Khanfir, Berrin Pehlivan, Oscar Matzinger, Roger Stupp, Raphael Moeckli, Abderrahim Zouhair
Journal: Journal of Thoracic Oncology (2007)
Trib1 and Trib2 but Not Trib3 Degrade C/EBPá and Induce Acute Myelogenous Leukemia
Authors: Priya Dedhia, Karen Keeshan, Maria Vega, Sacha Uljon, Lanwei Xu, Olga Shestova, Candice Romany, Stephen C Blacklow, Warren S. Pear
Journal: Blood (2008)
In utero exposure to 25-hydroxyvitamin D and risk of childhood asthma, wheeze, and respiratory tract infections: A meta-analysis of birth cohort studies
Authors: Haixia Feng, Pengcheng Xun, Katharine Pike, Andrew K. Wills, Bo L. Chawes, Hans Bisgaard, Wei Cai, Yanping Wan, Ka He
Journal: Journal of Allergy and Clinical Immunology (2016)
A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.
Authors: A. A. Meluch, J. C. Bendell, J. D. Peyton, P. Rudolph, M. S. Rubin, C. D. Webb, F. A. Greco, J. R. Infante, H. A. Burris, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2010)

4108 Background: Neoadjuvant chemoradiation therapy is a standard treatment for localized esophageal cancers. The combination of carboplatin (C), paclitaxel (P), 5-FU and radiation therapy (RT) showed a path CR rate of 38% in a previous phase II study. Overexpression of VEGF and/or EGFR in esophageal cancers is associated with a poor prognosis. Both bevacizumab (B) and erlotinib (E) have antitumor activity in multiple solid tumors and are known radiosensitizers. This phase II study evaluated the combination of carboplatin, paclitaxel, 5-FU, bevacizumab, and erlotinib with RT as preoperative treatment of localized esophageal cancers. Methods: Eligibility included previously untreated stage I, II or III surgical candidates with histologically confirmed cancer of the esophagus or GE junction. The treatment regimen was: C: AUC 5 d 1, 22, P: 200 mg/m2 d 1, 22, 5-FU: 225 mg/m2/d IV C1 d 1-35, B: 15 mg/kg d 1, 22, and E: 100 mg PO d 1-42. RT was 1.8 Gy M-F to a total dose of 45 Gy. Patients were restaged between weeks 9-11 and had surgical resection between weeks 12-14. Results: 62 subjects enrolled, 59 currently available for analysis. Median age 64 (43-76), 54 M: 5F, ECOG PS 0 37 (63%). Adenocarcinoma 56 (95%), SCC 3 (5%). Pretreatment clinical stage: I 1 (2%), II 25 (42%), III 30 (51%). Common grade 3/4 toxicities: neutropenia (46%, 10% fever and neutropenia), mucositis (39%), diarrhea (27%), esophagitis (22%), rash (15%), and fatigue (15%). Other significant AEs: 1 G3 peripheral arterial thrombosis, 2 G4 wound complications. 3 treatment related deaths; 1 GI bleed and 2 post op deaths. 42 (71%) subjects have undergone surgical resection, with 3 still undergoing neo-adjuvant treatment. Path CR = 17 (30%); micro residual disease = 13 (23%); macro residual disease = 8 (14%). Conclusions: This multicenter phase II study of chemotherapy plus B and E with RT shows a path CR rate comparable to historical chemoradiation trials. Toxicity was not significantly increased compared to other neoadjuvant combination regimens for esophageal cancer. Given the potential difficulty to build upon this regimen with added agents, the further development of this regimen for patients with esophageal cancers is limited. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Genentech Genentech
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
Authors: Ryuki Hashida, Takumi Kawaguchi, Masafumi Bekki, Masayuki Omoto, Hiroo Matsuse, Takeshi Nago, Yoshio Takano, Takato Ueno, Hironori Koga, Jacob George, Naoto Shiba, Takuji Torimura
Journal: Journal of Hepatology (2016)
Interleukin-17–Producing Neutrophils Link Inflammatory Stimuli to Disease Progression by Promoting Angiogenesis in Gastric Cancer
Authors: Tuan-Jie Li, Yu-Ming Jiang, Yan-Feng Hu, Lei Huang, Jiang Yu, Li-Ying Zhao, Hai-Jun Deng, Ting-Yu Mou, Hao Liu, Yang Yang, Qi Zhang, Guo-Xin Li
Journal: Clinical Cancer Research (2016)

Purpose: Elevated levels of neutrophils have been associated with poor survival in various cancers, but direct evidence supporting a role for neutrophils in the immunopathogenesis of human cancers is lacking.Experimental Design: A total of 573 patients with gastric cancer were enrolled in this study. Immunohistochemistry and real-time PCR were performed to analyze the distribution and clinical relevance of neutrophils in different microanatomic regions. The regulation and function of neutrophils were assessed both in vitro and in vivoResults: Increased neutrophil counts in the peripheral blood were associated with poor prognosis in gastric cancer patients. In gastric cancer tissues, neutrophils were enriched predominantly in the invasive margin, and neutrophil levels were a powerful predictor of poor survival in patients with gastric cancer. IL17+ neutrophils constitute a large portion of IL17-producing cells in human gastric cancer. Proinflammatory IL17 is a critical mediator of the recruitment of neutrophils into the invasive margin by CXC chemokines. Moreover, neutrophils at the invasive margin were a major source of matrix metalloproteinase-9, a secreted protein that stimulates proangiogenic activity in gastric cancer cells. Accordingly, high levels of infiltrated neutrophils at the invasive margin were positively correlated with angiogenesis progression in patients with gastric cancer.Conclusions: These data provide direct evidence supporting the pivotal role of neutrophils in gastric cancer progression and reveal a novel immune escape mechanism involving fine-tuned collaborative action between cancer cells and immune cells in the distinct tumor microenvironment. Clin Cancer Res; 23(6); 1575-85. ©2016 AACR.
P3-077: EGFR mutations and response to tyrosine kinase inhibitors therapy in NSCLC patients previously treated with chemotherapy
Authors: Lucio Crinó, Vienna Ludovini, Lorenza Pistola, Irene Floriani, Maura Betti, Rita Chiari, Dario Giuffrida, Cristina Scuderi, Francesca R. Tofanetti, Maurizio Tonato
Journal: Journal of Thoracic Oncology (2007)
John Hugh Ross
Authors: John Wood
Journal: BMJ (2016)

John Hugh Ross, war hero and the outstanding Hereford doctor of his generation, died quietly in his sleep at home on 8 July, 2016. Born in Hampstead in 1920, he qualified as a doctor in 1950 after distinguished war service, had married while a student, and came to Hereford as consultant physician in 1961. Jean and he had four children, who grew up in Hereford.

Many of the best aspects of Hereford's NHS hospitals were planned, designed, and pushed through by John. Always fully committed to a successful NHS he founded the Hereford postgraduate medical centre (one of the first in the West Midlands region), which bears his name. Proper staff accommodation at the County Hospital, the development of a coronary unit and intensive care unit, and the introduction of computed tomography scanning are a few examples of improvements that came early to Hereford as a result of John’s vision, foresight, and eloquence. He introduced renal dialysis to Hereford. He was always a fine teacher, and generations of doctors in training enjoyed the kindness and hospitality of John …
Diagnosis and Classification of Diabetes Mellitus
Journal: Diabetes Care (2010)

OF DIABETES MELLITUS -Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of differentorgans, especially the eyes, kidneys, nerves, heart, and blood vessels.Several pathogenic processes are involved in the development of diabetes.These range from autoimmune destruction of the ␤-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action.The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues.Deficient insulin action results from inadequate insulin secretion and/or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action.Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia.Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred vision.Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia.Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the nonketotic hyperosmolar syndrome.Long-term complications of diabetes include retinopathy with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing gastrointestinal, genitourinary, and Section on gestational diabetes diagnosis
Integration of DC vaccination in the primary treatment of adults with GBM: update of the HGG-2006 phase I/II trial
Authors: Stefaan Van Gool, Hilko Ardon, Wim Maes, Isabel Lopes, Stefan Rutkowski, Eckhart Kaempgen, Christof Kramm, Johannes Wolff, Frank Van Calenbergh, Steven De Vleeschouwer
Journal: Neuro-Oncology (2008)
Development and Preliminary Usability and Accuracy Testing of the EBMT Gvhd App to Support Graft Versus Host Disease Diagnosis and Scoring According to NIH Criteria, By the EBMT Complications and Quality of Life Working Party
Authors: Schoemans Helene, Kathy Goris, Raf Van Durm, Jasper Van Hoof, Hildegard T. Greinix, Daniel Wolff, Steven Z. Pavletic, Stephanie J. Lee, Johan Maertens, Sabina De Geest, Fabienne Dobbels, Rafael F. Duarte
Journal: Blood (2015)
Republicans Critical of White House for Zika Reaching the United States
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Enhanced Survival with Implantable Scaffolds That Capture Metastatic Breast Cancer Cells <i>In Vivo</i>
Authors: Shreyas S. Rao, Grace G. Bushnell, Samira M. Azarin, Graham Spicer, Brian A. Aguado, Jenna R. Stoehr, Eric J. Jiang, Vadim Backman, Lonnie D. Shea, Jacqueline S. Jeruss
Journal: Cancer Research (2016)

Abstract The onset of distant organ metastasis from primary breast cancer marks the transition to a stage IV diagnosis. Standard imaging modalities often detect distant metastasis when the burden of disease is high, underscoring the need for improved methods of detection to allow for interventions that would impede disease progression. Here, microporous poly(ϵ-caprolactone) scaffolds were developed that capture early metastatic cells and thus serve as a sentinel for early detection. These scaffolds were used to characterize the dynamic immune response to the implant spanning the acute and chronic foreign body response. The immune cell composition had stabilized at the scaffold after approximately 1 month and changed dramatically within days to weeks after tumor inoculation, with CD11b+Gr1hiLy6C− cells having the greatest increase in abundance. Implanted scaffolds recruited metastatic cancer cells that were inoculated into the mammary fat pad in vivo, which also significantly reduced tumor burden in the liver and brain. Additionally, cancer cells could be detected using a label-free imaging modality termed inverse spectroscopic optical coherence tomography, and we tested the hypothesis that subsequent removal of the primary tumor after early detection would enhance survival. Surgical removal of the primary tumor following cancer cell detection in the scaffold significantly improved disease-specific survival. The enhanced disease-specific survival was associated with a systemic reduction in the CD11b+Gr1hiLy6C− cells as a consequence of the implant, which was further supported by Gr-1 depletion studies. Implementation of the scaffold may provide diagnostic and therapeutic options for cancer patients in both the high-risk and adjuvant treatment settings. Cancer Res; 76(18); 5209–18. ©2016 AACR.
P2-250: A Phase II Study of Gleevec (Imatinib Mesylate) Plus Taxotere (Docetaxel) in Patients with Advanced Non-Small Cell Lung Cancer
Authors: John R. Eckardt, Ann Schmidt, M White, A Leonard, Alfred O. Greco, Nelida N. Sjak-Shie
Journal: Journal of Thoracic Oncology (2007)
Personal Sensing: Understanding Mental Health Using Ubiquitous Sensors and Machine Learning
Authors: David C. Mohr, Mi Zhang, Stephen M. Schueller
Journal: Annual Review of Clinical Psychology (2017)

Sensors in everyday devices, such as our phones, wearables, and computers, leave a stream of digital traces. Personal sensing refers to collecting and analyzing data from sensors embedded in the context of daily life with the aim of identifying human behaviors, thoughts, feelings, and traits. This article provides a critical review of personal sensing research related to mental health, focused principally on smartphones, but also including studies of wearables, social media, and computers. We provide a layered, hierarchical model for translating raw sensor data into markers of behaviors and states related to mental health. Also discussed are research methods as well as challenges, including privacy and problems of dimensionality. Although personal sensing is still in its infancy, it holds great promise as a method for conducting mental health research and as a clinical tool for monitoring at-risk populations and providing the foundation for the next generation of mobile health (or mHealth) interventions.
Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-relatedquality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.
Authors: Somnath Mukherjee, Chris Hurt, Peter Dutton, John A. Bridgewater, Thomas Crosby, Alec Mcdonald, Stephen Falk, Ross A. Abrams, Tim Maughan, Gareth Griffiths
Journal: Journal of Clinical Oncology (2014)

4126 Background: HRQL in pancreatic CRT trials have not been widely reported. In SCALOP, registered patients (n=114) received Gem and Cape induction chemotherapy (4 cycles) and non-progressing patients (n=74) were randomized to conformal RT (50.4Gy/28 fractions/5.5 weeks) in combination with Gem (300mg/m2 weekly) or Cape (830mg/m2 bd on days of RT). SCALOP demonstrated superior overall survival (15.2 mo vs 13.4 mo, HR 0.39, p=0.012) and lower Grade 3/4 hematological toxicity (18% v 0%, p=0.008) in the Cape-CRT arm (Mukherjee, Lancet Oncol, Apr 2013). The SCALOP trial was funded by Cancer Research UK (CR UK 07/040). Methods: HRQL was assessed with EORTC QLQ-C30 (generic domains) and EORTC PAN26 (pancreas specific) at Week 0 (pre-treatment), Week17 (pre-CRT), Week23 (post-CRT) and follow-up (Weeks 26, 39). The difference in change in function and symptom scores between trial arms from pre-CRT baseline (week 17) to later time-points were analysed using Wilcoxon rank sum tests. Results: HRQL form completion was 93%, 82%, 65%, 68% and 58% respectively across the time-points. Compared to pre-CRT baseline (week 17), at the end of CRT (week 23), patients on Cape-CRT arm experienced significantly better HRQL outcomes in terms of cognitive functioning (p=0.04), fatigue (p=0.05), bloating (p=0.04) and dry mouth (p=0.03). The differences were no longer significant at week 26 or 39 apart from cognitive function scores (p=0.01) and dry mouth (p<0.01), which remained significant at week 39. Conclusions: The better HRQL in the Cape-CRT arm complements the outcome from the main trial and further supports the use of Cape rather than Gem as concomitant chemotherapy with radiation in LAPC. Clinical trial information: NCT01032057.
131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission
Authors: Mazyar Shadman, Ajay K. Gopal, Pamela S. Becker, David G. Maloney, Barbara Pender, Andrei R. Shustov, Raya Mawad, Britt Kammerer, Oliver W. Press, John M. Pagel
Journal: Blood (2013)